1920 MCKINNEY AVENUE, DALLAS, TX
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Announces Closing of up to $8 Million Registered Direct Offering
Investor Presentation
To Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks
Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update
Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine
Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor
Q2
Q1
FY 2025
Q3
Amended Annual Report
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
S-1
Notice of Exempt Offering of Securities
PRE 14A
Definitive Proxy Statement
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Correspondence
Submission Upload
S-1MEF
Free Writing Prospectus